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Abstract
Background: The aim of the study was to examine the prevalence of and factors associated with antidepressant
(AD) prescriptions in order to draw a comprehensive picture of prescribing practices in Switzerland.
Method: We conducted a population-based, cross-sectional descriptive study using a large Swiss healthcare claims
database, covering approximately 13% of the Swiss population. AD prescription was determined by identifying
patients (N = 105,663) with health claims data of at least 1 AD prescription in the year 2016. AD medication was
identified using ATC-codes classified by the World Health Organisation. Univariate, bivariate and multivariate
analyses using logistic regression were performed.
Results: The extrapolated 1-year prevalence of AD prescription was 8.7% (95% CI, 8.7–8.8) with two thirds of AD
recipients being female and the average age being 59 years (SD = 19.1). The regional distribution of prescription rates
varied between cantons and ranged from 6.5 to 11.7%. Logistic regression revealed higher prescription rates among
females compared to males (OR: 1.52) and an increased probability of AD prescription by age up until 54 years (OR:
2.25) and≥ 85 years (OR: 2.32). Comorbidity is associated with higher odds (OR: 3.26 with 1–2 comorbidities) and
enrollment in a managed care plan (compared to standard care) with lower odds for an AD prescription (OR: 0.85).
Conclusion: This study is the first in Switzerland to describe the prevalence of and factors associated with AD
prescription based on a large health claims database reflecting routine care. The results provide important information
about regional variation, prescription source, and potential over-prescription in the treatment of depressive disorders.
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Background
Antidepressants (ADs) are the most commonly prescribed
class of psychotropic drugs with properties of reducing
symptoms of low mood and motivation [1]. They are pre-
dominantly used for the treatment of depressive disorders,
a highly prevalent condition, associated with high economic
burden and personal suffering [2]. Besides psychothera-
peutic approaches, AD medication is an evidence-based
treatment that is recommended by international guidelines
for moderate to severe depression as well as for chronic
courses of the disorder (e.g. [3, 4]). The use of AD for mild
forms of depression is not a first line treatment but can be
considered after a careful weighing of benefits and risk,
most notably adverse side effects. Therefore, guidelines for
depression differentiate their recommendations for AD use
according to severity and form of depression.
The prescription rates of ADs have increased sub-
stantially over the last few decades worldwide. In the
National Health and Nutrition Examination Surveys
(2005–2008) 11% of all Americans aged 12 and older
reported having taken an AD within the past month, in-
dicating an increase in prescription rate by 400% since
the time period 1988 to 1994 [5]. The number of AD
prescriptions issued in England has more than doubled
over a period of 13 years, according to analyses based
on the Prescription Cost Analysis Survey [6]. Similar
trends are observed in many other industrialised coun-
tries (e.g., [7, 8]) and also in patients with somatic
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conditions, such as coronary heart disease, which in-
volve the danger of potentially adverse interactions [9].
Attempts to explain the increase in AD prescriptions
and AD use have raised concerns about inappropriate
health care. There is evidence that the increase in AD
prescription is driven by long-term use of AD [10], but
researchers also argue that the widespread use is likely
due to extension of indications for AD treatment [11].
Another underlying factor for the increase in AD use is
suspected to be overprescription in less severe forms of
depression. This aspect is particularly relevant given
that a large volume of patients with mild to moderate
depression are treated in primary care, where psycho-
pharmacological medication is the most commonly ap-
plied form of treatment [12]. Moreover, the rise in AD
prescription has also been linked to the introduction
and use of new AD classes, such as selective serotonin
reuptake inhibitors (SSRIs) (e.g., [10]) and serotonin-
norepinephrine reuptake inhibitors (SNRIs), which are
associated with better tolerability. These findings give
reason to assess the class of ADs being prescribed and
the type of provider that prescribes AD medication.
Reliable and representative data for the outpatient
treatment of depressed patients is fragmentary but pre-
liminary data indicates that the Swiss population is
treated mainly with medication [13]. One population-
based source of information about levels of distress and
health service use is the Swiss national health survey
(Swiss Health Survey (SHS) [14]). The survey is con-
ducted via telephone interviews and a subsequent ques-
tionnaire in a five-year cycle. While the SHS provides a
valuable data source for the health status, health behav-
iour and health services use in the Swiss population, in-
formation are based on self-reports and refers to the
utilisation of an array of drugs and health services. The
assessment method used might lack precision about the
specific type and source of the prescription and carries
the risk of inaccurate recalling and reporting. This type
of information needs to be complemented with object-
ive and fine-grained data on psychopharmacological
drug use. In summary, data availability on AD dispens-
ing can be considered incomplete [14]. The Swiss
healthcare system is organised in a decentralised man-
ner with the possibility of accessing primary and sec-
ondary care free of choice. A central registry for
medication dispensing does not exist. Routine data
based on insurance claims provide a unique source of
information in order to increase our understanding of
AD prescription practices.
The objective of the current study was 1) to estimate
the AD prescription prevalence in Switzerland including
regional variations, 2) to determine factors associated
with AD use, and 3) to quantify the prescription rate by
AD classes and type of health care provider.
Methods
Study design and study population
The present study used a cross-sectional and
population-based approach. The analysis was based on
routine data from the Helsana group, a large health in-
surer covering approximately 13% of the Swiss popula-
tion. Health insurance is obligatory in Switzerland,
which means that all Swiss residents are required to
contract basic health insurance on the private market.
Every insured person chooses a monthly premium and
a deductible ranging from Swiss Francs (CHF) 300 to
2500 per year. Health care plans comprise either stand-
ard care models or managed care models, including
family doctor and telemedicine models. Health insur-
ance claims data were used from all patients insured
with Helsana in 2016, a collective of ca. 1.17 million in-
dividuals. The recorded insurance claims cover almost
all health care and pharmacy invoices, including costs
of health care use and prescription drugs. Data are ap-
proximately representative of the Swiss population. Ac-
cording to the Swiss national ethical and legal
regulations, ethical approval from the local ethics com-
mittee (ethical committee of the canton Zurich) was
not needed for the study.
Identification of patients with AD use
For the purpose of the current analysis all insurees who
were prescribed at least 1 AD in 2016 were included in
the analysis. AD medication was grouped according to
the Anatomical Therapeutic Chemical (ATC) classifica-
tion system of the World Health Organisation [15]. This
system categorises drugs according to their therapeutic
and chemical characteristics. ADs were classified under
N06Ax, with the fourth level indicating the class of AD
as follows: 1) tricyclic ADs (TCAs, code N06AA), 2)
selective serotonin reuptake inhibitors (SSRIs, code
N06AB), 3) monoamine oxidase inhibitors (MAOIs,
codes N06AF +N06AG), and 4) other ADs (N06AX),
which subsume nonuniform underlying mechanisms of
action (atypical AD), such as serotonin-norepinephrine
reuptake inhibitors (SNRIs) and tetracyclic ADs [15].
Population and prescriber characteristics
Population characteristics included gender, age groups,
regional variables such as language and area of resi-
dence, health insurance plan (managed care or standard
plan) and type of deductible class (low: ≤ CHF 500, high:
> CHF 500), and amount and type of comorbid chronic
conditions (CCCs).
Regional variables included the greater regions of
Switzerland, which are reference areas defined by the
Swiss Federal Office of Statistics (Zurich, Espace Mittel-
land, Lemanic region, Northwestern Switzerland, Eastern
Switzerland, Ticino, and Central Switzerland) and the 26
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member states (cantons) of the Swiss confederation at
canton-level. The area of residence displayed the level of
urbanisation and was classified into the categories
“urban” and “rural”, according to the national commu-
nity typology of the Swiss Federal Office of Statistics
[16]. Urban and intermediary (urban area) included (1)
municipalities of small, medium-large and large agglom-
erations or outside an agglomeration, and (2) dense
urban areas and rural centres (periurban municipalities
with medium and high density, rural centre municipal-
ities). Rural areas were defined as (1) low-density periur-
ban communities, and (2) rural, central and peripheral
communities.
A total of 21 CCCs were identified using a proxy vari-
able for diagnoses developed on the basis of medication
prescriptions related to chronic conditions [17]. For each
CCC, the point-prevalence was calculated by dividing
the number of persons with at least one medication pre-
scription in one of the defined ATC-groups by the total
of patients within the given year.
Characteristics of the prescription patterns comprise
the prescription source (type of health care provider)
and the class of ADs. In Switzerland, physicians are the
only legal health care provider, who are allowed to pre-
scribe drugs. Defined by their practice speciality, the fol-
lowing provider categories were grouped: general
practitioner (GP) only, psychiatrist only, other medical
specialist only (e.g., gastroenterologist), hospital ambula-
tory only and combination of providers. The combin-
ation category refers to all people, who received their
AD prescription from two different types of providers
(e.g., GP and psychiatrist or another specialist; or psych-
iatrist and another specialist, etc.). This is the case for
individuals who received more than one prescription
from at least two different providers.
Statistical analyses
Frequencies and proportions are reported in absolute
numbers and percentages of the sample. Chi-square-
tests and Wilcoxon rank-sum tests were used to com-
pare the proportions of baseline characteristics and the
presence of CCCs in persons with and without AD pre-
scription. Chi-square-tests were used to test the associ-
ation between the type of provider of AD prescriptions
and the area of residence of AD recipients. Prevalence
rates are provided both raw and extrapolated to the en-
tire Swiss population using census data from the Swiss
Federal Office of Statistics. The direct comparison be-
tween the raw and the adjusted results allows us to test
generalizability of our data to the entire Swiss popula-
tion. The procedure of extrapolation was used to adjust
for age, gender and canton of residence. Multivariable
logistic regression was employed to examine factors as-
sociated with AD prescription (dependent variable).
Independent variables included in the regression model
were age groups (15–24 (reference group), 35–44, 45–
54, 55–64, 65–74, 75–84, ≥85 years), gender (female or
male), insurance plan (managed care or standard plan),
type of deductible class (low or high deductible), resi-
dence area (rural or urban), and number of comorbid
conditions. Estimates are presented as odds ratios
(ORs) with 95% confidence interval (CIs). All analyses
were performed using R version 3.2.0 (R Development
Core Team 2015). A p-value < 0.05 was considered sta-
tistically significant.
Results
Prescription prevalence and description of the study
population
Our procedure identified 105,663 persons (male: 6.2%,
female: 11.7%) who received one or more AD prescrip-
tions in 2016, representing a 1-year AD prescription
prevalence of 9.0% (95%-CI: 9.0–9.1%) in the study
population covering more than 1.17 million health insur-
ance members. The extrapolated overall prevalence is
8.7% (95%-CI: 8.7–8.8%) and remains 6.2% for men and
11.7% for women after extrapolating to the general Swiss
population. Characteristics of the study population and
the groups with and without AD prescriptions are pre-
sented in Table 1.
Two thirds of all AD recipients were female, and the
average age of the sample was 59 years (SD = 19.1). Of
all AD users, 11.2% were adolescents or young adults
(age 15–34) whereas 41% of the AD receivers are aged
≥65 years. The prescription prevalence in age group ≥65
years was 16.2% (data not shown). Almost half of the
female AD users were ≥ 65 years old (44%) compared to
35% of the male AD users aged ≥65 years. Extrapolated
and unadjusted prevalence rates did not differ in age-
related subgroups (Additional file 1: Figure S1). Approxi-
mately half of the AD recipients were part of the
managed care plan (51.6%), whereas almost two thirds
of persons without AD prescriptions (64.2%) were in-
sured with this type of plan. Overall, comorbid diseases
were more prevalent in the patient group receiving AD
prescriptions compared to the group of patients without
AD prescriptions (Table 2). For instance, 50.1% of the
patients with AD use also received treatment for cardio-
vascular diseases compared to approximately 21.3% of
patients without AD use. Other conditions, which were
more prevalent in AD recipients than in persons without
AD prescription were acid-related disorders (47.6% vs.
17.0%), epilepsy, psychoses, pain, iron deficiency an-
aemia, Parkinson’s disease and osteoporosis.
Regional variations
The regional distribution shows that the proportions of
individuals using AD were similar across the greater
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regions of Switzerland in the study population and gen-
erally reflect the overall prescription rate (Ticino:
10.9%; see Table 1). However, on a canton-level, there
were significant differences in the prevalence rates
(Fig. 1), with the highest prevalence in Basel-Stadt
(11.9%) and the lowest in Zug (6.5%) when extrapolat-
ing to the regional distribution of the Swiss population.
The unadjusted and extrapolated prevalence rates
differed in some cantons and can be found in the elec-
tronic (Additional file 2: Figure S2).
Factors associated with AD prescription
The results of the multivariable logistic regression are
displayed in Table 3. The odds of receiving an AD were
1.52 times higher for women than for men (OR: 1.52,
95%-CI: 1.50–1.54), and AD prescription increased with
age until 54 years, with the highest likelihood of AD pre-
scription for people ≥85 years (OR: 2.32, 95%-CI: 2.24–
2.41). The odds for AD prescription were smaller in
patients covered with managed care compared to pa-
tients covered with the standard health insurance plan







Total 1,169,489 (100) 105,663 (100) 1,063,826 (100)
Gender
Male 567,102 (48.5) 34,927 (33.1) 532,175 (50.0)
Female 602,387 (51.5) 70,736 (66.9) 531,651 (50.0)
Age yrs. Mean (SD) 43.4 (24.4) 59.3 (19.1) 41.8 (24.3)
Age group (yrs.)
0–14 180,099 (15.4) 178 (0.2) 179,912 (16.9)
15–24 125,114 (10.7) 3895 (3.7) 121,219 (11.4)
25–34 140,438 (12.0) 7872 (7.5) 132,566 (12.5)
35–44 152,784 (13.1) 12,914 (12.2) 139,870 (13.1)
45–54 160,529 (13.7) 18,741 (17.7) 141,788 (13.3)
55–64 142,547 (12.2) 18,696 (17.7) 123,851 (11.6)
65–74 128,998 (11.0) 16,481 (15.6) 112,517 (10.6)
75–84 92,173 (7.9) 15,957 (15.1) 76,216 (7.2)
≥ 85 46,807 (4.0) 10,929 (10.3) 35,878 (3.4)
Region
Zurich 278,505 (23.8) 24,481 (23.2) 254,024 (23.9)
Espace Mittelland 224,446 (19.2) 21,213 (20.1) 203,233 (19.1)
Lemanic region 188,171 (16.1) 17,208 (16.3) 170,963 (16.1)
Northwestern Switzerland 160,304 (13.7) 13,976 (13.2) 146,328 (13.8)
Eastern Switzerland 145,167 (12.4) 13,425 (12.7) 131,742 (12.4)
Ticino 71,389 (6.1) 7786 (7.4) 63,603 (6.0)
Central Switzerland 101,507 (12.4) 7574 (7.2) 93,933 (8.8)
Area of residence
Urban area 912,328 (78.0) 83,854 (79.4) 828,474 (77.9)
Rural area 257,161 (22.0) 21,809 (20.6) 235,352 (22.1)
Managed Care
Yes 737,434 (63.1) 54,472 (51.6) 682,962 (64.2)
No 432,055 (36.9) 51,191 (48.4) 380,864 (35.8)
Franchise
High 308,618 (26.4) 10,351 (9.8) 298,267 (28.0)
Low 860,871 (73.6) 95,312 (90.2) 765,559 (72.0)
AD Antidepressant; For the definition of the variables area of residence (urban vs. rural), managed care (Yes, No), and Franchise (High vs. Low): see
Methods section
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(OR: 0.85, 95%-CI: 0.84–0.86). The majority of both AD
recipients and people without AD prescription (90 and
72%, see Table 1) set a high deductible. Patients with a
high deductible were less likely to receive ADs compared
to those with a low deductible (OR: 0.44, 95%-CI: 0.43–
0.45). Receiving AD prescription was significantly associ-
ated with the level of urbanization (lower for patients
living in rural than in urban areas (OR: 0.94, 95%-CI:
0.93–0.96). The odds of having an AD prescription in-
creased with the number of comorbid diseases and was
3.25 times higher for persons with 1–2 comorbid condi-
tions (OR: 3.26, 95%-CI: 3.20–3.32) and 13.79 times
higher for patients showing ≥5 comorbid conditions
(OR: 13.79, 95%-CI: 13.45–14.14) compared to AD users
without such a condition.
Class and amounts of ADs prescribed
Number and frequencies of individuals with prescrip-
tions by AD class and sociodemographic variables are
displayed in Table 4. The most commonly prescribed
drug classes were SSRIs (52.3%) and other ADs (51.1%)
followed by TCAs (13%) (Table 4). The most commonly
prescribed other ADs were: Mirtazapine (15.6%;
N06AX11 = atypical AD), Trazodone (11.3%; N06AX05 =
atypical AD), Venlafaxine (9.7%; N06AX16 = SNRI), and
Duloxetin (7.9%; N06AX21 = SNRI) (data not shown).
Another commonly prescribed AD from the class “other
AD” was St. John’s wort (14.6%; N06AX25), a herbal me-
dicinal product.
With regard to gender differences in prescribed AD
class, it was apparent that women receive more SSRIs
than men, whereas male AD recipients received more
other ADs (e.g. Mirtazapine) compared to female AD
users (SSRI: 49.7% male and 53.5% female; other ADs:
53.7% male and 49.8% female; p < 0.001). The level of
urbanization did not vary meaningfully between the pre-
scription rates in the drug classes (urban vs. rural area).
Prescription provider
With regard to the source of prescription, data shows
that 53.6% of the persons with ADs received their pre-
scription by a GP only compared to 16.9% individuals
receiving medication from a psychiatrist only (Table 5).
The residual category “combination of providers” refers
to all people who received two or more AD prescriptions
by more than one different providers (16.3%) When










Acid related disorders 231,616 (19.8) 50,245 (47.6) 181,371 (17.0) 56,306 (1) < 0.001a
Bone diseases (osteoporosis) 21,143 (1.8) 5007 (4.7) 16,136 (1.5) 5618.5 (1) < 0.001a
Cancer 15,955 (1.4) 3076 (2.9) 12,879 (1.2) 2064.2 (1) < 0.001a
Cardiovascular diseases (incl. hypertension) 279,956 (23.9) 52,975 (50.1) 226,981 (21.3) 43,782 (1) < 0.001a
Dementia 20,062 (1.7) 6808 (6.4) 13,254 (1.2) 15,395 (1) < 0.001a
Diabetes mellitus 56,381 (4.8) 10,877 (10.3) 45,504 (4.3) 7581.5 (1) < 0.001a
Epilepsy 33,742 (2.9) 13,474 (12.8) 20,268 (1.9) 40,354 (1) < 0.001a
Glaucoma 38,163 (3.3) 6719 (6.4) 31,444 (3.0) 3525.2 (1) < 0.001a
Gout, Hyperuricemia 18,380 (1.6) 2818 (2.7) 15,562 (1.5) 900.13 (1) < 0.001a
HIV 2365 (0.2) 417 (0.4) 1948 (0.2) 212.07 (1) < 0.001a
Hyperlipidemia 125,564 (10.7) 23,948 (22.7) 101,616 (9.6) 17,242 (1) < 0.001a
Intestinal inflammatory diseases 5144 (0.4) 1135 (1.1) 4009 (0.4) 1065.7 (1) < 0.001a
Iron deficiency anemia 56,746 (4.9) 10,527 (10.0) 46,219 (4.3) 6570.1 (1) < 0.001a
Migraines 12,958 (1.1) 3252 (3.1) 9706 (0.9) 4110.9 (1) < 0.001a
Pain 106,865 (9.1) 29,862 (28.3) 77,003 (7.2) 51,163 (1) < 0.001a
Parkinson’s disease 10,846 (0.9) 4233 (4.0) 6613 (0.6) 11,979 (1) < 0.001a
Psychoses 35,061 (3.0) 19,466 (18.4) 15,595 (1.5) 95,027 (1) < 0.001a
Respiratory illness (asthma, COPD) 99,180 (8.5) 16,164 (15.3) 83,016 (7.8) 6954.1 (1) < 0.001a
Rheumatologic conditions 138,197 (11.8) 29,732 (28.1) 108,465 (10.2) 29,694 (1) < 0.001a
Thyroid disorders 44,201 (3.8) 10,161 (9.6) 34,040 (3.2) 10,880 (1) < 0.001a
Tuberculosis 883 (0.1) 169 (0.2) 714 (0.1) 108.55 (1) < 0.001a
CCCs Classification of comorbid chronic conditions is based on medication prescriptions related to the disorder; aChi-square test
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considering the geographic area, in rural areas ADs are
prescribed more often by GPs only compared to Psychia-
trists only whereas the opposite is the case in urban
areas (Table 5).
Discussion
The aim of the current study was to draw an accurate
picture of the AD prescription prevalence and practices
in the Swiss health care system based on data of a large
health insurer. By using a health claims database that
covers 1.17 million insurees, we identified 105,663 pa-
tients who were prescribed at least 1 AD medication in
the year 2016. Overall, the rate of 8.7% for the use of
any AD in Switzerland is slightly higher than the average
of 7.2% detected in a large population survey in 27 Euro-
pean countries [18] and compared to the prescription
prevalence of 7.4% in a German study using health
claims data approach [19]. The most commonly pre-
scribed AD classes were SSRIs and other ADs (mostly
SNRIs), which were far more prevalent than TRCs and
MAOIs. This pattern is not surprising and consistent
with studies in other European countries, who demon-
strate that the increase in AD prescription is largely
driven by an increase in the dispensing of SSRIs and
drugs in the other AD group [10, 7]. González-López et
al. found that the rise in the latter group is primarily
explained by increased dispensing of Trazodone, Venla-
faxine, and Mirtazapine, the three most commonly pre-
scribed drugs from the other AD group in our study.
The demographic characteristics of AD users broadly
reflect previous findings that demonstrate a higher
prevalence of AD use in women and older people (e.g.,
[19, 7, 10, 20]. Our analysis revealed that women are
50% more likely than men to receive ADs, and that pre-
scription increases with age, posing a particular high
likelihood of AD prescription in people ≥85 years old.
While the present data and analysis does not allow to
draw conclusions about the appropriateness of AD pre-
scription as part of the treatment of a given depressive
disorder, the embedding of our results in the context of
depression prevalence is important to identify possible
indications of inappropriate health care. In inter-
national epidemiological studies, the 12-month preva-
lence of depressive disorders is 7% [21]. In Switzerland,
a population survey revealed a 12-month prevalence of
major depression of 5.2% [12] which contrasts with the
AD prescription rate of 8.7% in our study. While data
has consistently shown that depression is more com-
mon in women, the Swiss study shows that women only
have a 25% higher prevalence of depressive disorders
compared to men. Yet, our analysis revealed that
women are two times more likely to receive any AD
Fig. 1 Adjusted AD prescription rates by Swiss cantons in the year 2016. Copyright geodata Swiss Federal Statistical Office / swisstopo
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compared to males. This finding applies to all classes of
AD except for MAO inhibitors. One explanation for a
higher AD prescription rate in women compared to
men might be an overall higher rate of comorbid men-
tal health issues in women, for which AD treatment is
indicated, such as anxiety disorders, insomnia, and
pain, while increased help-seeking in women compared
to men might be another reason [22].
Our analysis showed that the likelihood of AD pre-
scription rises with age and that the very old people
have higher odds for AD prescription compared to
younger adults. Due to our procedure of extrapolating
age-related prevalences to the general population, we
can rule out that under- or overrepresentation of cer-
tain age groups in our sample accounts for this age
effect. There is supporting evidence that high age is a
risk factor for AD prescription and use [23–25]. For ex-
ample, in a study investigating time trends of AD pre-
scription rates across lifetime, a rise in AD prescribing
in all age groups, with a threefold increase of AD pre-
scription in the older age group relative to the middle-
aged group was observed [23]. This is notable in view
of inconsistent results about the prevalence of depres-
sive disorders in the elderly. Indeed, a recent
epidemiological study in six European countries
showed that affective disorders are highly prevalent in
the older population: the 12-month prevalence of
affective disorders in people aged 65 to 84 years was
13.7% [26]. However, it has also been argued that major
depressive disorder is relatively rare amongst old people
but that minor depression explains the prevalence of
depression in older age [27]. A finding from a Swiss
population health survey demonstrates that the per-
ceived depression decreases as people get older, indicat-
ing that elderly people experience and report less
depressive symptomatology [13]. Additionally, evidence
for high rates of AD prescription in older populations
despite absence of a diagnosis of a major depressive dis-
order or significant depressive symptoms [25], points
toward potential overuse of AD in the very old. Finally,
our finding of relatively high AD prescription rate of
16.2% in individuals aged ≥65 is in contrast with a re-
cent Swiss survey according to which only 4.7% of the
people above 65 years received ADs [13]. While mul-
tiple factors might influence high AD prescription in
the old population, lacking alternatives of psychosocial
and psychotherapeutic care might partially contribute
to this finding.
Higher number of comorbid somatic conditions in-
creased the likelihood of AD use by up to 13 times.
Table 3 Logistic regression analysis for predictors of AD
prescription
Variables AD prescription
OR (95% CI) P
Age group (yrs.)a
0–14 0.03 (0.03–0.03) < 0.001
15–24 1.0
25–34 1.50 (1.45–1.55) < 0.001
35–44 2.03 (1.97–2.10) < 0.001
45–54 2.25 (2.18–2.32) < 0.001
55–64 1.81 (1.76–1.87) < 0.001
65–74 1.34 (1.29–1.38) < 0.001
75–84 1.67 (1.61–1.72) < 0.001
≥ 85 2.32 (2.24–2.41) < 0.001
Sex (female) 1.52 (1.50–1.54) < 0.001
Insurance plan (managed care)b 0.85 (0.84–0.86) < 0.001
High deductiblec 0.44 (0.45–0.43) < 0.001
Area of residence (rural)d 0.94 (0.93–0.96) < 0.001
Number of Comorbiditiese
1–2 3.26 (3.20–3.32) < 0.001
3–4 6.68 (6.54–6.83) < 0.001
≥ 5 13.79 (13.45–14.14) < 0.001
OR Odds Ratio, CI Confidence Interval; aage group 15–24 is the reference
group; bmanaged care is the reference group; c high deductible is the
reference group; drural area is the reference group; eNo comorbidities is the
reference group










Total 55,236 (52.3a) 13,708 (13.0a) 255 (0.2a) 53,971 (51.1a)
Gender
Female 37,864 (68.5) 9411 (68.7) 145 (43.1) 35,222 (65.3)
Male 17,372 (31.5) 4297 (31.3) 110 (56.9) 18,749 (34.7)
Age group
0–14 103 (0.2) 5 (0.1) 0 (0.0) 78 (0.1)
15–24 2284 (4.1) 309 (2.3) 5 (2.0) 1875 (3.5)
25–34 4469 (8.1) 738 (5.4) 20 (7.8) 4033 (7.5)
35–44 7205 (13.0) 1358 (9.9) 41 (16.1) 6701 (12.4)
45–54 9751 (17.7) 2371 (17.3) 51 (20.0) 10,026 (18.6)
55–64 9357 (16.9) 2842 (20.7) 43 (16.9) 9043 (17.9)
65–74 8216 (14.9) 2672 (19.5) 52 (20.4) 7958 (14.7)
75–84 8044 (14.6) 2264 (16.5) 25 (9.8) 8125 (15.1)
≥ 85 5807 (10.5) 1149 (8.4) 18 (7.1) 5522 (10.2)
Area of residence
Urban area 44,086 (79.8) 10,776 (78.6) 205 (80.4) 42,790 (79.3)
Rural area 11,150 (20.2) 2932 (21.4) 50 (19.6) 11,181 (20.7)
SSRIs selective serotonin reuptake inhibitors, TCA tricyclic antidepressants,
MAOIs monoamine oxidase inhibitors; apercentages are related to the
subsample with AD prescriptions (n = 105,663); all other percentages as related
to the total amount per AD class
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Although this result might reflect the growing body of
evidence demonstrating the high rate of somatic comor-
bidities in depression [28], it should further be investi-
gated, whether increasing prescription rates of AD for
non-depressive and off-label indications might be one
factor contributing to that result [29].
Differences in the regional distributions of AD pre-
scription rates are another important finding that
warrants further exploration. There are substantial dif-
ferences in prescription rates on a canton level, ranging
from 6.5 to 11.9% when adjusting for regional distribu-
tion of the Swiss population. This might be due to differ-
ent health services structures in these regions, e.g.
variations in physician density. The comparison of our
prevalence rates with statistics on physician density per
inhabitant and the net benefit costs per insured persons
in the year 2016, the following picture emerges: There is
a clear congruence of low prescription rates in cantons
with a low density of medical doctors and a similar but
not conclusive relationship of high AD prescription rates
in cantons with high density of medical doctors [30, 17].
This pattern remains stable for all cantons with low pre-
scription rates and most cantons with high prescription
rates after extrapolating to the general Swiss population.
This finding is in line with a systematic review, which
identified a consistent significant association between
physician density and health care consumption [31]. A
German study examining regional differences in AD pre-
scription based on health claims data also argued that
low prescription rates in some regions might be due to a
lack of health care professionals [19].
Lastly, we examined the characteristics of the prescrip-
tion patterns as a function of the prescription source or
health care provider. We found that the majority of pa-
tients was prescribed the AD medication exclusively by a
GP. Just a small fraction of ADs was prescribed by psy-
chiatrists only, physicians only, who work in hospital
ambulatories, and by other specialists. GPs and out-
patient psychiatric practices are usually the first point of
contact for patients with mental complaints and provide
the major part of outpatient care for individuals with
mental disorders. There is evidence that in primary care
depression and mixed anxiety disorders account for 60
to 75% of AD prescriptions [32, 33]. Our finding thus
might reflect a generally low referral rate of patients
with depression to specialized care – in Switzerland only
13% [13]. An additional finding paralleling this interpret-
ation is the higher AD prevalence found in individuals
registered with standard care plans compared to insurees
registered with Managed Care. From a health care sys-
tem perspective managed care models are associated
with higher referral rates in Switzerland [34]. While two
thirds of our sample were enrolled in Managed Care,
this only applies to a vastly smaller fraction of the Swiss
general population [35]. Taken together, these important
observations prompt questions of whether the intersec-
tion between primary and secondary care bears chal-
lenges in the Swiss health care system, which lead to a










Combination of providers N (%) χ2 (df) P-value
All ADs 56,669 (53.6) 17,832 (16.9) 6374 (6.0) 7589 (7.2) 17.199 (16.3) 782.00 (4) < 0.001
Urban 43,302 (76.4) 15,261 (85.6) 5324 (83.5) 6069 (80.0) 13.694 (79.6)
Rural 13,367 (23.6) 2571 (14.4) 1050 (16.5) 1520 (20.0) 3.505 (20.4)
SSRIs 24,614 (23.3) 8230 (7.8) 2636 (2.5) 3296 (3.1) 16.460 (29.8) 389.73 (4) < 0.001
Urban 18,875 (76.7) 7097 (86.2) 2222 (84.3) 2641 (80.1) 13.111 (79.7)
Rural 5739 (23.3) 1133 (13.8) 414 (15.7) 655 (19.9) 3.349 (20.3)
TCA 6130 (5.8) 1134 (1.1) 936 (0.9) 798 (0.8) 4.710 (34.4) 30.38 (4) < 0.001
Urban 4727 (77.1) 946 (83.4) 768 (82.1) 629 (78.8) 3.674 (78.0)
Rural 1403 (22.9) 188 (16.6) 168 (17.9) 169 (21.2) 1.036 (22.0)
MAOIs 56 (0.1) 60 (0.1) 9 (0.001) 13 (0.001) 117 (45.9) 2.78 (4) 0.595
Urban 48 (81.4) 49 (81.7) 9 (100.0) 10 (76.9) 91 (78.1)
Rural 11 (18.6) 11 (18.3) 0 (0.0) 3 (23.1) 26 (21.9)
Others 22,586 (21.4) 7181 (6.8) 3002 (2.8) 4075 (3.9) 17.127 (31,7) 218.25 (4) < 0.001
Urban 17,317 (76.7) 6026 (83.9) 2488 (82.9) 3255 (79.9) 13.580 (79.3)
Rural 5269 (23.3) 1155 (16.1) 514 (17.1) 820 (20.1) 3547 (20.7)
χ
2 Chi square, GP General Practitioner; aThe provider type refers to patients with prescriptions made by this type of provider only; Chi-square-tests are related to
the overall test of association between provider type and area of residence (urban vs. rural); See Methods section for further definitions of variables
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high load of and potentially inappropriate AD treatment
delivered in primary care.
Strengths and limitations
We would like to point out three major weaknesses of
our study design and methodology. Firstly, as we are
examining AD prescription rates based on health claims
data, we cannot be sure that persons, who receive an
AD prescription take this medication as prescribed.
Since insurance claims data require a patient to pick up
the prescribed drug in a pharmacy, it would be rather
unlikely for an individual to obtain the prescribed medi-
cation without consuming it. Secondly, it is important to
mention that the data of this study are not entirely rep-
resentative of the Swiss general population, with minor
differences being observed regarding sex, age and the re-
gion of residence. In order to correct for potential
biases, we provided raw and adjusted results. However,
several strengths of the data need to be stressed as well:
The results presented in the study were based on a
population of over 1 million insured subjects from all re-
gions of Switzerland; the obligatory health insurance
provided is defined at the federal level and it is the same
for all health insurance companies; the data quality is ex-
cellent due to a high degree of completeness. For these
reasons a high degree of generalizability of the data can
be assumed.
Lastly, and most importantly, this study lacks any
diagnostic information about the people who receive
AD. This makes conclusions of the (in-) appropriate-
ness of AD treatment difficult. Thus, the data illustrates
the prevalence, patterns, amount and source of AD pre-
scriptions in a collective of insured patients but it does
not necessarily relate to AD prescription in diagnosed
patients with depression. Yet, we believe that AD pre-
scription rates serve as a proxy for the treatment of de-
pression and depressive symptoms allowing for
comparisons of depression prevalence rates and AD
prescription rates which might shed light on the appro-
priateness of mental health services in Switzerland.
This is important given the lack of complete and ap-
propriate data with regard to psychotropic drug dispens-
ing in the Swiss health care system. For example, there
is one data source in Switzerland indicating that more
than two thirds of patients with less severe forms of de-
pression are treated exclusively with ADs in primary
care [12]. This issue is of particular interest given that
the proportion of patients expressing a preference of
psychological treatment is three times higher than those
preferring pharmacological treatment [36]. Furthermore,
this “real-world information” analysis adds objective and
reliable data to previous work which was mainly based
on self-report information. Especially in the context of
stigma related to mental disorders, it is important to
have access to unbiased data, which are not influenced
by social desirability, a lack of reliability and other
sources of bias related to self-reporting.
Conclusions
Overall, our analyses showed that AD prescriptions are
more prevalent than expected, particularly in older age
groups, and are subject to regional variation. In
Switzerland, AD treatment seems to be primarily deliv-
ered by GPs. Taken together these results call for fur-
ther, more detailed analyses in this important field.
Results from routine data are essential since it provides
a basis and starting point for further investigation of
prescription practise. A continued effort to build on
these data would enable researchers and clinicians to
track timing of current AD treatments as well as time
trends of AD treatment in the Swiss health care system.
AD is primarily used for the treatment of depressive
disorders and the pharmacological treatment of depres-
sion is subject to specific recommendations, guidelines
and principles [4]. Further investigation of AD prescrip-
tion patterns, such as duration, combination, switching,
and augmentation, as well as treatment trajectories of
AD prescription will increase our understanding of the
pharmacological treatment practices of mental disor-
ders and particularly depressive disorders. The current
analysis can be an important first step to carry forward
a meticulous investigation of routine data regarding AD
prescription in Switzerland.
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